Category Archives: Uncategorized

Kraig Biocraft Laboratories Announces Second Production Facility, Three Advanced Spider Silk Strains, and New Diapausing System

New Architecture lays foundation for Higher Output, continuous Batch Production, and prepares Company for Spider Silk delivery to European-based Global Luxury Market Leader

ANN ARBOR, Mich., July 14, 2025 — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”, “Kraig”, or “Kraig Labs”), a world leader in spider silk technology*, announces the addition of a second parallel production facility, three new advanced spider silk strains, and the immediate launch of a new diapausing system for production. This marks three critical advancements in the Company’s high-performance spider silk manufacturing and commercialization to significantly increase production yields and spun silk quality.

Jon Rice, COO of Kraig Labs, recently traveled to the Company’s production facilities in Southeast Asia to organize the launch of this next exciting phase of Kraig’s production plan for 2025 and 2026, including a second, parallel production facility, three new spider silk strains, and a shift to controlled diapause for production.

A central part of these advancements is the adoption of a second parallel rearing center. A lease for the second facility is being finalized, and parental strain rearing is expected to begin there within the next 30 days.

Kraig Labs completed the development of three new spider silk strains, which are now in the field. These strains, developed over the last year, were designed to complement the Company’s existing BAM-1 hybrid by improving hybrid vigor and increasing silk yield. One of these stains was designed as a replacement for an existing BAM-1 parent lines. Two of these strains were bred to produce silkworms suitable for controlled diapause.

Diapause refers to the silkworm’s natural wintering period, a process which can be replicated with a 90-day cold treatment of the silkworm eggs. Diapausing silkworm strains are the gold standard for producing premium silk. One of the Company’s key initial target customers is a widely-renowned producer of the world’s finest fabrics and garments, crafted from the highest-quality fibers. Kraig Labs is committed to meeting those standards with its spider silk and the shift to diapausing egg production, along with the addition of a second facility, are key drivers in achieving that goal and increasing production.

Thus far, the Company’s production center has operated under a batch production model, bypassing diapause and limiting production to 8 or 9 batches per year. The shift to parallel facilities and the diapausing of eggs (artificial wintering utilizing cold storage treatment) will enable nearly continuous production. These two facilities will operate in tandem to feed that production. While egg production from one facility enters cold storage, the second facility will prepare the next rearing cycle, ensuring a continuous flow of eggs to supply production operations. This new collaborative production system will dramatically expand production capacity far beyond what any single facility could produce independently.

As Kraig Labs rolls out these significant improvements to its operations, the Company is undertaking a production transition period, which includes a 90-day cold treatment cycle for the new diapausing hybrid eggs. This wintering process is widely recognized for yielding stronger, finer silk and significantly larger cocoons than non-diapausing silk. Over the next several months, operational emphasis will shift away from finished silk production and focus on expanding parent line populations and generating the next round of hybrid eggs that Kraig Labs plans to begin releasing in the fourth quarter.

“Deploying two separate rearing centers for our parent lines is a key part of our strategy to build a reliable and scalable supply chain that can address the demand for spider silk and support year-round production,” said Kim Thompson, Founder and CEO of Kraig Labs. “This plan, which is the brainchild of our chief sericulture expert, Dr. Kumar, will provide the throughput necessary to support large-scale commercial production and a buffer against potential disruption.”

In parallel with these advancements in production operations, Kraig Labs is pleased to announce it has completed the latest batch of BAM-1 finished spider silk. With this newest batch of finished silk complete, the Company has now accumulated approximately one-third of the total spider silk required to fulfill a material request from a globally renowned European fashion house.

“This latest batch brings us another step closer to delivering premium spider silk materials to one of the most recognized names in fashion. The shift to a diapausing hybrid system reflects our long-term vision to deliver the highest quality spider silk at commercial scale,” said Rice. “By making this investment in time, infrastructure, and production strategy, we are positioning ourselves to meet the demand we see forming.”

Today’s announcement marks a significant milestone in Kraig’s commercialization roadmap, accelerating the Company’s goal of establishing the world’s first cost-effective, environmentally responsible spider silk production platform. The transition to diapausing hybrid rearing and parallel rearing operations enhances supply chain resilience and long-term throughput, as Kraig Labs responds to growing interest from industry.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Announces Senior Management Trip to Southeast Asia to Oversee Expansion of Spider Silk Production

This trip was scheduled in coordination with Dr. Nirmal Kumar, the Company’s lead sericulture expert. Dr. Kumar’s expertise and guidance have been instrumental in developing and executing the Company’s production expansion initiatives and optimizing the deployment of its proprietary spider silk technologies in the field.

In addition to meetings with key partners, senior management will review current spider silk inventories in preparation for anticipated shipments to strategic customers later this year. This review highlights the Company’s commitment to upholding high standards of quality and readiness as it progresses toward fulfilling commercial orders.

“Our continuing expansion in Southeast Asia has been one of the highlights of this year,” said Jon Rice, COO of Kraig Labs. “This trip will build on that success, allowing management to work side-by-side with our team and partners to continue strengthening the future of spider silk production. We are incredibly proud of what we’ve accomplished so far in 2025, and we look forward to taking the next steps during this trip to grow production and prepare for the upcoming commercial deliveries.”

The Company’s momentum in scaling up production reflects its broader mission to bring sustainable, high-performance spider silk materials to market and establish a robust commercial supply chain.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Issues a Letter to Shareholders on Recent Advancements and Potential Recombinant Spider Silk Deliveries in 2025

ANN ARBOR, Mich., June 3, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, issues a letter to shareholders.

Dear Shareholders,

We recently received inquiries from several of our shareholders. In preparing those responses, we realized that we should share the contents with the broader Kraig Labs community. Many had questions related to last week’s announcement of the development of the new production strain and the potential for commercial deliveries in 2025.

The development of a new spider silk production transgenic has been a key part of our production roadmap since 2023 and a primary objective of our genetics team during the last 18 months. Our longstanding plans were to field a new strain of silkworm for our double hybrid production system in the Summer of 2025. To be frank, we were unsure whether we could meet that ambitious schedule. We were, therefore, ecstatic to announce that we created another world’s first development on schedule. This and many of our other laboratory announcements are not only significant; they’re foundational technology building blocks to our success.

Our current single hybrid system, utilizing BAM-1, has already shown massive improvement in robustness and silk production output. The newly announced strain is another significant improvement in our production, moving us a significant step closer to a more powerful double hybrid. The double hybrid model is designed to significantly improve our silk production rate; we expect by as much as 25+% per month, so this is something that we were very excited to share with our shareholders.

We are no longer experiencing the robustness challenges we faced with single-strain rearing. Before the rollout of the BAM-1 hybrid in 2024, our silkworms lacked the robustness to deal with the silkworm diseases and environmental stress that are frequently present in the field. In terms of robustness and disease tolerance, the BAM-1 appears to be on par with the Chinese commercial silk hybrid, which is the gold standard in that region for the production of mundane silk.    

Now, this doesn’t mean that we are invincible. Globally, between 10% to 30% of all silk production with robust double hybrids is lost due to a handful of diseases and adverse weather conditions. This is just a part of working with these living production systems. It is a fact that is reflected in global silk economics. Since rolling out the BAM-1, we have dealt with these routine challenges and have weathered these events with similar or identical effects as mundane silk producers utilizing the Chinese hybrid. Right now, the region’s sericulture operators are in their rainy season, which is typically the worst time for silkworm rearing. Production of our BAM-1 strains and production of mundane silk producers utilizing Chinese hybrids are negatively impacted during this cycle. That is a normal part of silkworm rearing and is something that all silkworm producers encounter as a normal part of the business.

In the past, before we introduced BAM-1, the effects on our silkworms were significantly magnified and effectively stymied our growth. In short, there has been a revolution in our spider silk production technology over the past 14 months due to the introduction of BAM-1 and other improvements in the field and laboratory. As we meet our marks toward the initiation of the double hybrid, we anticipate our gains to accelerate further.

Regarding inventory calculation, our current inventory figures track finished raw reeled silk. In the first quarter of this year, we stockpiled several hundred kilograms of cocoon that are now waiting to be processed into finished silk. The reason inventory did not increase in our financial report was because that report tracked finished silk or material form. After considering these questions, and in light of the fact that we are moving from nominal inventory to larger scale production, we will expand the scope of our work-in-progress (WIP) material inventory to include recombinant spider silk cocoon that has been completed but not reeled. You can expect us to begin adding completed recombinant spider silk cocoon to our WIP to all future inventory balances. 

We are 100% focused on the production of spider silk for commercial delivery. Over the last year, we’ve been able to move faster to deliver on that commitment. As a great example, we are in regular communication with three major Global brands that are standing by to receive their first shipments of materials. The first is an internationally renowned high-end luxury fashion brand that has already accepted a quote from Kraig Labs. The second is a world leader in high-end performance sportswear with an approved budget to buy silk from us. The third is one of the world’s top 5 performance athletic equipment producers, looking for spider silk to integrate into their top-performing products. Supplying products to these three entities is the focus of our current production. Currently, we expect to begin deliveries to these customers in the second half of this year. That will be a significant milestone for Kraig Labs, our shareholders, and material science.

I believe the future for Kraig Labs and spider silk has never been brighter, and we thank you for your continued support.

Kim Thompson, CEO

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Announces New Spider Silk Parental Strain for Expanded Commercial Production

Company Expands Capacity to Meet Material Demand and Scale Inventory by developing new parental Strain for Production.

ANN ARBOR, Mich., May 28, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, announces today the successful development of a new recombinant spider silk parental line, purpose-built for large-scale commercial production.

This newly developed strain represents the third commercial production line created by Kraig Labs as it executes on its strategy to expand output capacity. The addition of this next-generation silk-producing line comes as the Company ramps up production to fulfill current material requests and strategically build inventory for future sales.

“Our team continues to deliver on key milestones as we scale the commercialization of spider silk,” said Company Founder and CEO, Kim Thompson. “With the development of this new production strain, we are not only increasing our ability to meet existing demand, but also reinforcing the foundation for our future growth. This new strain is part of the production roadmap we outlined in 2024 and a key part of our transition to a full double-hybrid production system.”

This latest strain is part of Kraig Labs’ broader development pipeline, which includes several additional parental lines currently in advanced stages of development. These lines are designed to enable a transition to a double hybrid production model, expected to deliver significant performance improvements, including higher silk yields, increased colony resilience, and reduced overall production costs.

“As we prepare to implement double hybrid crosses into our production platform, we are opening the door to greater scalability, efficiency, and product consistency,” Thompson continued. “This is a key step forward in our mission to bring the power of spider silk to mainstream markets.”

The Company is continuing its focus on building a robust and scalable production system as it transitions from pilot operations to full-scale manufacturing.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Receives Business License to Begin Operations in Cambodia

New Location to Support Unprecedented 2025 Spider Silk Production Expansions

ANN ARBOR, Mich., May 15, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*,  announces today that it has officially received its business license to begin operations in the Kingdom of Cambodia. This milestone marks a significant step in the Company’s ongoing strategy to scale up and diversify its production capabilities in response to the exceptional success of its 2025 expansion initiatives.

The Company’s decision to launch operations in Cambodia is grounded in the continued positive momentum Kraig Labs has achieved through its expanded production efforts this year.

“This license represents more than just geographic growth—it’s a reflection of the strong foundation we’ve built through our 2025 production expansion,” said Jon Rice, COO of Kraig Labs. “Cambodia offers the right combination of climate, infrastructure, and opportunity to support the next phase of our spider silk production scale up. We are confident that this new location will play a role in helping continue to grow and diversity our production based for our spider silk materials.”

The Cambodian business license is expected to support the Company’s goals of increasing production capacity, while simultaneously diversifying its production footprint. As Kraig Labs embarks on this next phase of its business plan, it continues to invest in both research and infrastructure to advance the performance and scalability of its proprietary recombinant spider silk technologies.

Kraig Labs remains committed to strengthening its production pipeline and establishing a global footprint that supports the commercial roll-out of next-generation biomaterials.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Successfully Completes March/April Production Cycle; May Production Now Underway

Company Continues to Meet 2025 Scale-Up Targets

ANN ARBOR, Mich., May 6, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), a world leader in spider silk technology*, announces that it has successfully completed its March/April spider silk production run and is currently well underway with its May production cycle.

This steady progress reflects the Company’s continued execution against its 2025 production scale-up plan, which builds on the significant operational and technical advancements achieved throughout 2024. Spider silk production for March and April met internal performance benchmarks and production targets, reinforcing confidence in the expanded capacity and workflow improvements implemented earlier this year.

With May’s production already in progress, Kraig Labs is maintaining its momentum and remains on track to meet its full-year production capacity goals. These efforts support Kraig Labs’ broader strategy to transition recombinant spider silk from pilot-scale production to commercial viability across multiple markets.

“Our teams in Vietnam and the U.S. continue to demonstrate consistent execution and focus,” said Company Founder and CEO, Kim Thompson. “With each completed cycle, we are strengthening our manufacturing capabilities and moving closer to our goal of delivering commercial volumes of eco-friendly, performance fiber.”

The Company will provide further updates as it progresses through its 2025 production calendar.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Provides Production Update on Recombinant Spider Silk Operations

ANN ARBOR, Mich., April 21, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), a world leader in spider silk technology*, is pleased to provide an update on recombinant spider silk production. The Company continues to increase its production output and is now in the middle of its largest-ever batch of recombinant spider silk production.

Kraig Labs can now report that it has successfully completed the first half of its current production batch and those spider silk cocoons are being prepared for reeling into finished silk. This second half of this production cycle is expected to be complete in the next 14 days. 

This current production run marks a significant milestone, as the first simultaneous batches of BAM-1 produced in the Company’s newest facilities. The initial results have been highly encouraging, demonstrating the robustness of the BAM-1 hybrids and the efficiency of the expanded production infrastructure. The concurrent operation of multiple batches has proceeded smoothly, underscoring the scalability and reliability of the Company’s production model.

In addition to the progress in silk production, Kraig Labs has completed the production of all BAM-1 hybrid eggs designated for release over the next month. This achievement ensures a steady supply of high-quality hybrids for upcoming production cycles, aligning with the Company’s strategic objectives and production goals for 2025.

“The successful execution of simultaneous production batches in our new facilities demonstrates the scalability of our technology from batch processing to continuous flow manufacturing,” said Kim Thompson, Founder and CEO of Kraig Labs. “With this cycle nearing completion and the next generation of BAM-1 hybrids already prepared, we are in a strong position to rapidly accelerate the growth and commercialization of our spider silk.”

Kraig Labs remains committed to advancing the commercialization of its eco-friendly and high-performance spider silk fibers. The Company will continue to provide updates as it progresses toward its production and commercialization goals.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Announces the Launch of Advanced Gene-Splicing Program and New Transgenics

Company Adopting Advanced Gene Editing Platform Across All Commercial Silkworm Development Programs

ANN ARBOR, MI – April 15, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology[1], today announced the successful rollout of a next-generation molecular biology and gene-splicing platform. This powerful new system represents a major leap forward in the Company’s ability to create and refine genetically engineered spider silk and other advanced materials. The Company has already validated the technology with a newly created transgenic.

Leveraging cutting-edge advancements in gene editing, this platform enables more precise, efficient, and versatile manipulation of DNA. As a result, Kraig Labs has rapidly developed a new transgenic silkworm, which is now undergoing evaluation testing and commercial application assessment.

This breakthrough empowers Kraig Labs to significantly accelerate its R&D pipeline for advanced materials and enhance material performance.

“Our adaption of this technology represents a transformative advancement for Kraig Labs and our entire molecular biology program,” said Company Founder and CEO, Kim Thompson. “With this platform in place, we are dramatically expanding the speed, scope, and sophistication of our genetic engineering capabilities. The successful creation of new transgenics using this system confirms its effectiveness. We are experimenting with two such platforms and will likely adopt one of them for all of our ongoing and future commercial silkworm development.”

Kraig Labs is now actively transitioning all of its silkworm biotechnology programs to these next-generation platforms, which is expected to drive increased efficiency, consistency, and performance in spider silk production.

This development marks another milestone in the Company’s mission to lead the commercialization of high-performance spider silk materials for a broad range of end markets, including technical textiles, defense, performance apparel, and medical textiles.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com


[1]For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Biocraft Laboratories is Happy to Announce its New Director of Molecular Biology as it Accelerates Advanced Fibers Development

ANN ARBOR, Mich., April 7, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk-based super materials, is pleased to announce the appointment of Dr. Xiaoli Zhang as Director of Molecular Biology.

Dr. Zhang is a proven research and development leader in the field of molecular biology and bioengineering, with numerous groundbreaking accomplishments in spider silk and transgenic silkworms, including publication and citations in peer-reviewed scientific journals. Her research has been pivotal in optimizing the Company’s genetic engineering of silkworms to produce high-performance spider silk.

In the very short time she has worked directly with Kraig Labs, she has rapidly achieved significant breakthroughs in the development of brand-new spider silk-based fibers that target capabilities beyond the currently available materials. The Company is now accelerating the transition of these new developments out of the laboratory with a focus on large-scale commercialization of these revolutionary materials.

“We are thrilled to recognize Dr. Zhang’s invaluable contributions to the development of advanced biomaterials, including spider silk, by appointing her to the pivotal position of Director of our Molecular Biology laboratory and R&D center,” said Kim Thompson, CEO and Founder of Kraig Biocraft Laboratories. “Her expertise and leadership have been essential in driving the development of our next-generation spider silk technology and in our adoption of new genetic engineering technologies. As we continue to push the boundaries of what’s possible in material science, Dr. Zhang’s vision and dedication will be instrumental in shaping the future of biomaterials.”

Throughout her career, Dr. Zhang has demonstrated a commitment to innovation in genetic engineering, making her a recognized leader in the field. Her work at Kraig Labs has accelerated the Company’s ability to create new advanced biomaterials.

“I am honored to take on this new role at Kraig Biocraft Laboratories,” said Dr. Zhang. “The advancements we’ve made in spider silk production are just the beginning of what’s possible. I look forward to continuing our groundbreaking work and bringing this incredible material to market at scale.”

Dr. Zhang’s appointment underscores the Company’s commitment to scientific excellence and innovation in biomaterials. As Kraig Labs advances its commercial rollout of spider silk-based textiles, her leadership will be critical in ensuring continued success in the field of bioengineered materials.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Secures Four Registered Trademarks for SpydaSilk® Brand, to Advance Commercialization Strategy for Recombinant Spider Silk

ANN ARBOR, Mich., April 1, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or the “Company”), a world leader in recombinant spider silk technology, today announced that it has secured four registered trademarks for its SpydaSilk® brand. These trademarks represent a key milestone in the Company’s strategy to commercialize its revolutionary spider silk technology and position SpydaSilk® as a premium apparel brand.

“The registration of these trademarks reinforces our commitment to building SpydaSilk® into a globally recognized brand focused on quality and exceptional material performance,” said Kim Thompson, CEO and Founder of Kraig Labs. “With our spider silk production scaling up, we are positioning ourselves to introduce breakthrough products that merge sustainability with performance. We are actively engaging with industry leaders to explore collaborative opportunities that will bring our innovative materials to market.”

The Company’s proprietary recombinant spider silk fibers offer a combination of strength, elasticity, and softness, making them ideal for a range of high-value applications. Kraig Labs is engaging opportunities in luxury fashion and technical textiles to integrate its materials into next-generation products that redefine performance and sustainability standards.

With the recent expansion of its production operations, Kraig Labs remains focused on optimizing its recombinant spider silk output and finalizing product designs for commercialization. The Company anticipates that its dual-track approach—developing SpydaSilk® as a standalone brand while also collaborating with industry leaders—will accelerate the adoption of its technology and drive revenue growth.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com